Search Technologies
Displaying 1 - 10 of 225 results
Researchers at the University of Maryland have created hundreds of innovations that are available for licensing. Our Discovery Portfolio contains an exciting mix of vaccines, drug targets, therapeutics, devices and cutting edge techniques that promise to make a quantifiable impact on human health and the environment.
Search by keyword:
-
Functional Myelination of Neurons
Published Tuesday, May 7, 2024Summary This invention is a significant advancement in regenerative medicine, offering a novel stem cell-based therapy for demyelinating diseases. It utilizes melanocyte stem cells (MeSCs) from the skin to differentiate into cells capable of myelination, addressing diseases like...
Investigator(s): Thomas Hornyak and Sandeep Joshi
Categories: Therapeutics, Biologics, Stem Cells, Methods of Treatment
Docket: TH-2015-020
-
Adjustable Focus Magnetic Stimulation Coil
Published Friday, March 22, 2024Summary The Adjustable Focus Magnetic Stimulation Coil is a medical device for transcranial or transdermal magnetic stimulation (TMS) promising to enhance treatment of neurological disorders. Its unique coil design permits modulation of magnetic fields to penetrate deeper brain...
Investigator(s): L. Elliot Hong, Fow-Sen Choa, Qinglei Meng
Categories: Devices
Keyword(s): Transcranial Magnetic Stimulation (TMS), Neurological Diseases, Non-invasive Brain Stimulation
Docket: LH-2019-056
-
Identification of Toll-Like Receptor 2 (TLR2) Antagonists Using Computer-Aided Drug Design
Published Wednesday, March 6, 2024Toll-like receptors (TLR) are innate immune molecules involved in the detection of microbial and self-ligands released from damaged cells. At their C-termini, toll/interleukin-1 receptor (TIR) domains dimerize upon ligand binding, initiating a signaling cascade that results in the upregulation of inflammatory cytokines. Excessive signaling can...
Investigator(s): Alexander D. MacKerell, Stefanie N. Vogel
Categories: Platforms, Therapeutics
Keyword(s): TLR2, sepsis, anti-inflammation, TIR
Docket: SV-2010-075
-
Compositions and Methods to Evaluate Hepatobiliary/Gastrointestinal Health, Enterohepatic Circulation, and Drug Interactions
Published Wednesday, March 6, 2024Summary The patent describes a novel trifluorinated bile acid analogue, CA-sar-TFMA, designed for use as an imaging probe, diagnostic agent, or contrast agent in evaluating hepatobiliary/gastrointestinal health, enterohepatic circulation, and drug interactions. CA-sar-TFMA's is...
Investigator(s): James E. Polli, Jean-Pierre Raufman, Diana Vivian
Categories: Imaging
Keyword(s): Trifluorinated bile acid analogue, 19F MRI imaging probe, Hepatobiliary health, Gastrointestinal diagnostics, Enterohepatic circulation, Bile acid malabsorption
Docket: JP-2014-050
-
The Episodic Tool: innovative approach to teach clinical decision making
Published Monday, March 4, 2024Advanced health assessment serves as the foundational course in advanced practice nurse (APN) education in which students apply clinical decision-making skills to gather appropriate subjective and objective data and to begin to formulate diagnostic hypotheses. UMB’s team of professional nurse educators found that APN education...
Investigator(s): Veronica Quattrini, Amanda Roesch, Katelynn Dougherty Soper
Categories: Education/Training/Multimedia
Keyword(s): Teaching tool; Advanced practice nurse education; Advanced health assessment; Clinical judgment
Docket: VQ-2024-032
-
Preventing Metastatic Breast Cancer with Therapeutic Lectin
Published Monday, March 4, 2024UMB inventors led by Prof. Amy Fulton and Prof. David Weber have developed a novel recombinant protein – a lectin known as “rEMSL1” - and elucidated its structure, binding characteristics, and probable mechanism of action. The rEMSL1 construct has been optimized for expression from mammalian cell lines. In...
Investigator(s): Amy Fulton, David Weber, Raquel Godoy-Ruiz, Namita Kundu
Categories: Therapeutics
Keyword(s): Cancer; metastasis; stem cells; biologic; lectin
Docket: AF-2021-040
-
Methods and Systems for Controlling Magnetic Fields and Magnetic Field Induced Current
Published Monday, February 5, 2024Summary The patent US 10,773,096 B2 introduces a novel approach to non-invasive medical treatments, leveraging controlled magnetic fields and currents for deep brain stimulation (DBS). This technology promises enhanced precision in targeting neurological disorders, offering a...
Investigator(s): Elliot Hong, Fow-Sen Choa
Categories: Devices
Keyword(s): Deep brain stimulation (DBS), Transcranial Magnetic Stimulation (TMS), Non-invasive medical treatments, Magnetic field control, Neurological therapy
Docket: LH-2016-129
-
SYSTEM, APPARATUS AND METHOD FOR TRANSIENT ELECTRIC FIELD DETECTION AND DISPLAY
Published Monday, February 5, 2024Summary The patent US 10,758,740 B2 introduces a system for detecting and displaying transient electric fields induced by Transcranial Magnetic Stimulation (TMS). The patent describes a method and system for the precise measurement and visualization of TMS effects,...
Investigator(s): Elliot Hong, Fow-Sen Choa
Categories: Devices, Imaging devices
Keyword(s): Transcranial Magnetic Stimulation (TMS), Electric field detection, Neurology, Psychiatric treatment, Medical device calibration, Brain stimulation
Docket: LH-2015-028
-
Percutaneous Dilation Tracheostomy Device and Method of Using
Published Monday, December 11, 2023Summary The "Percutaneous Dilation Tracheostomy Device and Method of Using" (US 11,497,872 B2) describes a novel percutaneous dilation tracheostomy device. The patented device integrates multiple components into a single unit, enhancing safety and usability. The global...
Investigator(s): Joseph Rabin
Categories: Devices, Surgical devices
Keyword(s): Tracheostomy, Airway Management, medical device, Emergency Care, Tracheal Dilation
Docket: JR-2017-079
-
SMALL MOLECULE STAT3 INHIBITOR FOR TREATING TRIPLE NEGATIVE BREAST CANCER
Published Monday, December 11, 2023Summary The patent application describes the molecule LLL12B which targets STAT3 protein. STAT3 is pivotal in cancer progression. LLL12B is novel therapy that addresses an unmet need in TNBC and pancreatic cancer treatment. The breast cancer therapeutics market, valued at $28.8...
Investigator(s): Jiayuh Lin, Li Pan
Categories: Therapeutics, Small molecules
Keyword(s): • STAT3 Inhibitor, triple-negative breast cancer, pancreatic cancer, Targeted Cancer Therapy
Docket: JL-2022-040